接受抗逆转录病毒治疗的HIV感染患者的耐药性与死亡之间的关系——中国7个公共卫生机构艾滋病示范区，2010 - 2019年
Relationship Between Drug Resistance and Death in HIV-Infected Patients Receiving Antiretroviral Therapy - 7 PLADs, China, 2010-2019.
作者信息
Zhang Tianhao, Liao Lingjie, Shao Yiming, Feng Yi, Ruan Yuhua, Xing Hui
机构信息
State Key Laboratory of Infectious Disease Prevention and Control (SKLID), National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China.
出版信息
China CDC Wkly. 2021 Apr 2;3(14):291-297. doi: 10.46234/ccdcw2021.068.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: With increasing coverage of antiretroviral therapy (ART) for HIV-infected patients, more and more attention has been paid to the impact of HIV drug resistance on death in those patients in China.
WHAT IS ADDED BY THIS REPORT?: Among HIV-infected patients receiving ART, the risk of death is higher in patients with HIV drug resistance [adjusted odds ratio (AOR)=4.25, 95% confidence interval (CI): 2.10-8.62], with viral load ≥1,000 copies/mL but drug resistance untested (AOR=4.65, 95% CI: 1.74-12.39), and with neither viral load nor drug resistance being tested (AOR=17.52, 95% CI: 8.73-35.19) when compared with drug-sensitive patients.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: It is important to strengthen drug resistance monitoring and prevention in HIV-infected patients. While performing ART for HIV-infected patients, viral load testing and drug resistance testing should be carried out routinely and promptly.
关于该主题已知的信息有哪些？：随着对艾滋病毒感染患者抗逆转录病毒疗法（ART）覆盖范围的扩大，在中国，艾滋病毒耐药性对这些患者死亡的影响受到了越来越多的关注。
本报告新增了哪些内容？：在接受ART的艾滋病毒感染患者中，与药物敏感患者相比，艾滋病毒耐药患者的死亡风险更高[调整优势比（AOR）=4.25，95%置信区间（CI）：2.10 - 8.62]，病毒载量≥1000拷贝/毫升但未进行耐药性检测的患者（AOR = 4.65，95% CI：1.74 - 12.39），以及既未检测病毒载量也未检测耐药性的患者（AOR = 17.52，95% CI：8.73 - 35.19）。
对公共卫生实践有哪些启示？：加强对艾滋病毒感染患者的耐药性监测和预防非常重要。在为艾滋病毒感染患者实施ART时，应常规且及时地进行病毒载量检测和耐药性检测。
Zotero 插件